Reva Medical Files for IPO

Xconomy San Diego — 

San Diego-based Reva Medical, which is developing bioabsorbable stents for treating arterial disease, has filed for a $63 million IPO on the Australian Stock Exchange, according to PE Hub. Inteq Ltd., a boutique investment bank in Sydney, is serving as the lead underwriter. The company has raised about $57 million in venture capital funding from Domain Partners, Cereberus Capital Managemet, Brookside Capital, and Group Outcome, according to PE Hub.

By posting a comment, you agree to our terms and conditions.

2 responses to “Reva Medical Files for IPO”

  1. Has the FDA commented on the bioabsorbable stints which Reva is working on? Also, These stints have a huge upside, most bioabsorbable stints, I believe, are for “drug delivery?” only, not arterial disease. Good luck Reva!

  2. Garry Peacock says:

    Any idea who will be handling the IPO in the USA? Also any indication when and how much each share will be?
    Will this be a patented item and has the FDA approved the product?